Literature DB >> 19474064

Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains.

Olivier Clermont1, Hiran Dhanji, Mathew Upton, Tarek Gibreel, Andrew Fox, David Boyd, Michael R Mulvey, Patrice Nordmann, Etienne Ruppé, Jean Louis Sarthou, Thierry Frank, Sophie Vimont, Guillaume Arlet, Catherine Branger, Neil Woodford, Erick Denamur.   

Abstract

OBJECTIVES: Recently, a CTX-M-15 extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli O25b-ST131 clone, belonging to the B2 phylogenetic group and with a high virulence potential, has been reported all over the world, representing a major public health problem. The present study was carried out to develop a rapid and simple detection assay that identifies members of this clone.
METHODS: A total of 627 E. coli isolates of which 373 produced an ESBL, collected across four continents, were screened using a O25b-ST131 clone allele-specific PCR for the pabB gene.
RESULTS: One hundred and forty-three ESBL isolates were found positive with the assay. These isolates were all of O25b type and, when studied by multilocus sequence typing (25 cases), were all of ST131. The O25b-ST131 clone was found to produce ESBLs other than CTX-M-15, specifically CTX-M-2, -3, -14, -27, -32 and -61 as well as TEM-24. This clone represents 3% of non-ESBL B2 isolates originating from urinary tract infections in Paris.
CONCLUSIONS: We have developed a PCR-based assay that easily identifies a clone with high likelihood of producing ESBLs, including CTX-M-15.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19474064     DOI: 10.1093/jac/dkp194

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  110 in total

1.  Emerging antimicrobial resistance among Escherichia coli strains in bloodstream infections in Toronto, 2006-2016: a retrospective cohort study.

Authors:  Sophie Mineau; Robert Kozak; Melissa Kissoon; Aimee Paterson; Anthony Oppedisano; Firas Douri; Kate Gogan; Barbara M Willey; Allison McGeer; Susan M Poutanen
Journal:  CMAJ Open       Date:  2018-12-03

2.  Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region.

Authors:  Gisele Peirano; Akke K van der Bij; Daniel B Gregson; Johann D D Pitout
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

3.  High-resolution melting-curve analysis of ligation-mediated real-time PCR for rapid evaluation of an epidemiological outbreak of extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Hanna Woksepp; Cecilia Jernberg; Maria Tärnberg; Anna Ryberg; Alma Brolund; Michaela Nordvall; Barbro Olsson-Liljequist; Karin Tegmark Wisell; Hans-Jürg Monstein; Lennart E Nilsson; Thomas Schön
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

4.  Cooccurrence of Multiple AmpC β-Lactamases in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis in Tunisia.

Authors:  Thouraya Chérif; Mabrouka Saidani; Dominique Decré; Ilhem Boutiba-Ben Boubaker; Guillaume Arlet
Journal:  Antimicrob Agents Chemother       Date:  2015-10-12       Impact factor: 5.191

5.  Detection of OXA-48 carbapenemase in the pandemic clone Escherichia coli O25b:H4-ST131 in the course of investigation of an outbreak of OXA-48-producing Klebsiella pneumoniae.

Authors:  Dearbháile Morris; Edel McGarry; Meaghan Cotter; Virginie Passet; Maureen Lynch; Catherine Ludden; Margaret M Hannan; Sylvain Brisse; Martin Cormican
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

6.  CTX-M as the predominant extended-spectrum beta-lactamases among Enterobacteriaceae in Manila, Philippines.

Authors:  Guo-Bao Tian; Jemelyn Garcia; Jennifer M Adams-Haduch; Jennifer P Evangelista; Raul V Destura; Hong-Ning Wang; Yohei Doi
Journal:  J Antimicrob Chemother       Date:  2010-01-06       Impact factor: 5.790

7.  Production of KPC-2 carbapenemase by an Escherichia coli clinical isolate belonging to the international ST131 clone.

Authors:  Dearbháile Morris; Fiona Boyle; Catherine Ludden; Iris Condon; James Hale; Nuala O'Connell; Lorraine Power; Teck Wee Boo; Hiran Dhanji; Christian Lavallee; Neil Woodford; Martin Cormican
Journal:  Antimicrob Agents Chemother       Date:  2011-07-18       Impact factor: 5.191

8.  Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage.

Authors:  Gisele Peirano; Akke K van der Bij; Joshua L Freeman; Laurent Poirel; Patrice Nordmann; Michael Costello; Veronika L Tchesnokova; Johann D D Pitout
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

9.  First Report of Prevalence of CTX-M-15-Producing Escherichia coli O25b/ST131 from Iran.

Authors:  Mohammad Hasan Namaei; Masoud Yousefi; Masoud Ziaee; Alireza Salehabadi; Malaknaz Ghannadkafi; Elham Amini; Parvin Askari
Journal:  Microb Drug Resist       Date:  2017-02-16       Impact factor: 3.431

10.  Antibiotic selection of Escherichia coli sequence type 131 in a mouse intestinal colonization model.

Authors:  Frederik Boetius Hertz; Anders Løbner-Olesen; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.